VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2017

Jan 6, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2017-01-04

Reporting Person: BOGER JOSHUA S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-01-04	Common Stock	M	6500	$36.30	Acquired	274725	Direct
2017-01-04	Common Stock	S	200	$75.64	Disposed	274525	Direct
2017-01-04	Common Stock	S	4400	$76.95	Disposed	270125	Direct
2017-01-04	Common Stock	S	1900	$77.69	Disposed	268225	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-01-04	Stock Option (Right to Buy)	$36.30	M	6500	Disposed	2017-01-23	Common Stock (6500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	13286	Indirect
Common Stock	78200	Indirect

Footnotes

F1: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.

F2: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3: Open market sales reported on this line occurred at a weighted average price of $75.64 (range $75.22 to $76.06).

F4: Open market sales reported on this line occurred at a weighted average price of $76.95 (range $76.35 to $77.28).

F5: Open market sales reported on this line occurred at a weighted average price of $77.69 (range $77.41 to $78.04).

F6: Fully vested.